About Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial (ECH1) is a protein
from Homo sapiens identified by UniProt accession
Q13011, 328 residues long.
MolForge cross-references it against 0 known binders and
39 disease associations.
Target properties
| Protein name | Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial |
|---|
| UniProt accession | Q13011 |
|---|
| Gene | ECH1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 328 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (39)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.22
- platelet count · score 0.18
- platelet crit · score 0.06
- miotic rate · score 0.03
- aortic valve disease · score 0.02
- non-alcoholic steatohepatitis · score 0.02
- laryngotracheoesophageal cleft · score 0.01
- neoplasm · score 0.01
- breast cancer · score 0.01
- systemic juvenile idiopathic arthritis · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q13011-F1 | alphafold | PREDICTED | 88.17 | — |
Amino-acid sequence (328 residues)
MAAGIVASRR LRDLLTRRLT GSNYPGLSIS LRLTGSSAQE EASGVALGEA PDHSYESLRV TSAQKHVLHV QLNRPNKRNA MNKVFWREMV ECFNKISRDA DCRAVVISGA GKMFTAGIDL MDMASDILQP KGDDVARISW YLRDIITRYQ ETFNVIERCP KPVIAAVHGG CIGGGVDLVT ACDIRYCAQD AFFQVKEVDV GLAADVGTLQ RLPKVIGNQS LVNELAFTAR KMMADEALGS GLVSRVFPDK EVMLDAALAL AAEISSKSPV AVQSTKVNLL YSRDHSVAES LNYVASWNMS MLQTQDLVKS VQATTENKEL KTVTFSKL
Explore Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets